BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · IEX Real-Time Price · USD
24.88
+0.55 (2.26%)
At close: Apr 26, 2024, 4:00 PM
24.95
+0.07 (0.28%)
After-hours: Apr 26, 2024, 7:43 PM EDT
BridgeBio Pharma Revenue
In the year 2023, BridgeBio Pharma had annual revenue of $9.30M, a decrease of -88.02%. Revenue in the quarter ending December 31, 2023 was $1.75M, a -6.68% decrease year-over-year.
Revenue (ttm)
$9.30M
Revenue Growth
-88.02%
P/S Ratio
493.30
Revenue / Employee
$16,915
Employees
550
Market Cap
4.59B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organon & Co. | 6.26B |
| R1 RCM | 2.25B |
| Lantheus Holdings | 1.30B |
| Haemonetics | 1.27B |
| Halozyme Therapeutics | 829.25M |
| Doximity | 468.33M |
| CRISPR Therapeutics AG | 371.21M |
| Glaukos | 314.71M |
BBIO News
- 17 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - GlobeNewsWire
- 7 weeks ago - BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - BridgeBio Pharma Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe - Reuters
- 7 weeks ago - BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM - GlobeNewsWire
- 2 months ago - BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan - GlobeNewsWire